Showing results (31-40 of 279) with videos related to
Sort By:
Pageof 28
American Journal of Hematology|March 29, 2024
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and managementWilliam Shomali, Jason GotlibHematology. American Society of Hematology. Education Program|December 4, 2018
The new tool "<i>KIT</i>" in advanced systemic mastocytosisWilliam Shomali, Jason GotlibSeminars in Cancer Biology|February 6, 2004
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylateSteven Coutré, Jason GotlibInternational Journal of Molecular Sciences|April 3, 2021
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT InhibitorsWilliam Shomali, Jason GotlibNature Structural & Molecular Biology|December 25, 2010
Sequence-specific regulator Prdm14 safeguards mouse ESCs from entering extraembryonic endoderm fatesZiyang Ma, Tomek Swigut, Anton Valouev, et al.Genetics|September 25, 2003
Patterns of heteroduplex formation associated with the initiation of meiotic recombination in the yeast Saccharomyces cerevisiaeJason D Merker, Margaret Dominska, Thomas D PetesExpert Review of Hematology|November 19, 2010
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasmsStephen T Oh, Jason GotlibAmerican Journal of Hematology|August 25, 2006
A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significanceJon S Fukumoto, Jason GotlibCurrent Hematologic Malignancy Reports|August 30, 2018
Clinical Validation of KIT Inhibition in Advanced Systemic MastocytosisJohn H Baird, Jason GotlibCurrent Hematologic Malignancy Reports|April 29, 2010
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?Stephen T Oh, Jason GotlibPageof 28